欧洲多中心研究:COVID-19合并大血管闭塞机械取栓的早期结局
本研究为欧洲多中心队列研究,纳入法国、意大利、西班牙和比利时34家卒中中心的93例实验室确诊COVID-19合并大血管闭塞并接受机械取栓的患者。主要结局30天死亡率为29%,成功再灌注率为79.6%,早期神经改善率为19.5%,症状性颅内出血率为5.4%。淋巴细胞计数降低、天冬氨酸和乳酸脱氢酶升高与30天死亡率增加独立相关。
要点
- COVID-19合并大血管闭塞患者机械取栓后30天死亡率为29%。
- 成功再灌注率79.6%,但早期神经改善率仅19.5%。
- 淋巴细胞降低、天冬氨酸和LDH升高与30天死亡风险增加相关。
核心结论
- COVID-19患者机械取栓后30天死亡率为29%,不可忽视。
- 淋巴细胞计数、乳酸脱氢酶和天冬氨酸异常可能提示取栓后预后较差。
研究设计与样本
- 欧洲多中心队列研究,涉及法国、意大利、西班牙和比利时34家卒中中心。
- 数据收集时间为2020年3月1日至2020年5月5日。
- 纳入连续实验室确诊COVID-19合并大血管闭塞并接受机械取栓的患者,共93例。
- 中位年龄71岁(四分位距59-79),男性63例(67.7%)。
主要发现
- 成功再灌注(mTICI 2b-3)率为79.6%(74例,95% CI 71.3-87.8)。
- 30天死亡率为29%(27例,95% CI 20-39.4)。
- 早期神经改善率为19.5%(17例,95% CI 11.8-29.5)。
- 症状性颅内出血率为5.4%(5例,95% CI 1.7-12.1)。
- 死亡患者淋巴细胞计数显著更低,天冬氨酸和乳酸脱氢酶水平更高。
关键数值与推荐
- 调整年龄、初始NIHSS评分、ASPECTS和成功再灌注后,淋巴细胞计数每SD-log降低与30天死亡率增加相关(aOR 2.70,95% CI 1.21-5.98)。
- 天冬氨酸每SD-log升高与30天死亡率增加相关(aOR 2.66,95% CI 1.22-5.77)。
- 乳酸脱氢酶每SD-log升高与30天死亡率增加相关(aOR 4.30,95% CI 1.43-12.91)。
临床怎么用
- 对COVID-19合并大血管闭塞患者行机械取栓时,应关注30天死亡风险。
- 淋巴细胞计数降低、天冬氨酸和乳酸脱氢酶升高可能有助于识别预后较差的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Acute ischemic stroke and large vessel occlusion can be concurrent with the coronavirus disease 2019 (COVID-19) infection. Outcomes after mechanical thrombectomy (MT) for large vessel occlusion in patients with COVID-19 are substantially unknown. Our aim was to study early outcomes after MT in patients with COVID-19. METHODS: Multicenter, European, cohort study involving 34 stroke centers in France, Italy, Spain, and Belgium. Data were collected between March 1, 2020 and May 5, 2020. Consecutive laboratory-confirmed COVID-19 cases with large vessel occlusion, who were treated with MT, were included. Primary investigated outcome: 30-day mortality. SECONDARY OUTCOMES: early neurological improvement (National Institutes of Health Stroke Scale improvement ≥8 points or 24 hours National Institutes of Health Stroke Scale 0-1), successful reperfusion (modified Thrombolysis in Cerebral Infarction grade ≥2b), and symptomatic intracranial hemorrhage. RESULTS: We evaluated 93 patients with COVID-19 with large vessel occlusion who underwent MT (median age, 71 years [interquartile range, 59-79]; 63 men [67.7%]). Median pretreatment National Institutes of Health Stroke Scale and Alberta Stroke Program Early CT Score were 17 (interquartile range, 11-21) and 8 (interquartile range, 7-9), respectively. Anterior circulation acute ischemic stroke represented 93.5% of cases. The rate modified Thrombolysis in Cerebral Infarction 2b to 3 was 79.6% (74 patients [95% CI, 71.3-87.8]). Thirty-day mortality was 29% (27 patients [95% CI, 20-39.4]). Early neurological improvement was 19.5% (17 patients [95% CI, 11.8-29.5]), and symptomatic intracranial hemorrhage was 5.4% (5 patients [95% CI, 1.7-12.1]). Patients who died at 30 days exhibited significantly lower lymphocyte count, higher levels of aspartate, and LDH (lactate dehydrogenase). After adjustment for age, initial National Institutes of Health Stroke Scale, Alberta Stroke Program Early CT Score, and successful reperfusion, these biological markers remained associated with increased odds of 30-day mortality (adjusted odds ratio of 2.70 [95% CI, 1.21-5.98] per SD-log decrease in lymphocyte count, 2.66 [95% CI, 1.22-5.77] per SD-log increase in aspartate, and 4.30 [95% CI, 1.43-12.91] per SD-log increase in LDH). CONCLUSIONS: The 29% rate of 30-day mortality after MT among patients with COVID-19 is not negligible. Abnormalities of lymphocyte count, LDH and aspartate may depict a patient's profiles with poorer outcomes after MT. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT04406090.
引用
- Cagnazzo F, Piotin M, Escalard S, et al. European Multicenter Study of ET-COVID-19. Stroke. 2020. PMID: 33222617. doi:10.1161/STROKEAHA.120.031514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。